Abstract

Allogeneic blood cell transplantation is a new alternative to bone marrow transplantation. Preliminary data suggest that granulocyte-colony-stimulating factor (G-CSF)-mobilized peripheral blood progenitor cells from normal donors can provide rapid hematopoietic engraftment without significant increases in transplant-related morbidity. Potential advantages to donors include the elimination of an operation under general anesthesia. Twenty-one normal donors underwent high-dose (16 pg/kg/day for 5 days) G-CSF mobilization. Apheresis was performed on the fifth and sixth days of G-CSF administration, and apheresis components were analyzed by flow cytometry. Donor characteristics in relationship to apheresis yields were also analyzed. Apheresis components were analyzed according to donor weight. The median total numbers of white cells per kg, CD34+ cells per kg, and CD3+ cells per kg were 10.8 x 10(6), 7.2 x 10(8), and 295 x 10(8), respectively. Day 5 collections had significantly higher nucleated cell content and median CD34+ percentages than did Day 6 collections (0.71% on Day 5 vs. 0.58% on Day 6, p < 0.01). CD34+ content and total white cells were not related to age or sex. No donors experienced toxic effects that required their removal from the study. Day 5 is the optimal day for the harvest of normal-donor peripheral blood progenitor cells after mobilization with high-dose G-CSF. Older individuals are acceptable donors of allogeneic progenitor cells.

Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.